In conclusion, our findings show that YBX acts as a tumor promoter by targeting Myc and HIF1α to facilitate glycolysis, which is crucial to the malignant phenotypes of bladder cancer cells. This evidence concerns the gene HIF1A and urinary bladder cancer.